Eli Lilly Sells Baqsimi, a Hypoglycemia Treatment, to Amphastar for $500 Million in Cash
Eli Lilly offloads innovative hypoglycemia nasal spray, Baqsimi, to Amphastar Pharmaceuticals bolstering Amphastar's diabetes portfolio.
Eli Lilly has announced plans to sell Baqsimi, its innovative nasal spray for treating severe hypoglycemia in diabetic patients, to California-based Amphastar Pharmaceuticals (NASDAQ: AMPH). The deal, worth $500 million upfront and an additional $125 million after one year, includes up to $450 million in sales-based milestones.
Baqsimi, which was launched by Lilly in 2019, earned $139.3 million in sales across 27 countries last year.
Amphastar CEO Jack Zhang believes the acquisition aligns with their strategic vision to expand their proprietary products and enhance their diabetes portfolio. Meanwhile, Lilly remains committed to improving the lives of those with diabetes by focusing on the development of potential breakthrough treatments.
Reference: Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash. April 24, 2023 / yahoo! finance
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
